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OBJECTIVES: To describe the perinatal outcomes of type II and III selective fetal growth restriction (sFGR) in
monochorionic-diamniotic (MCDA) twin pregnancies treated with expectant management or laser ablation of
placental vessels (LAPV).
METHODS: Retrospective analysis of cases of sFGR that received expectant management (type II, n=6; type III,
n=22) or LAPV (type II, n=30; type III, n=9). The main outcomes were gestational age at delivery and survival rate.
RESULTS: The smaller fetus presented an absent/reversed ‘‘a’’ wave in the ductus venosus (arAWDV) in all
LAPV cases, while none of the expectant management cases presented arAWDV. The median gestational
age at delivery was within the 32nd week for expectant management (type II and III) and for type II LAPV,
and the 30th week for type III LAPV. The rate of at least one twin alive at hospital discharge was 83.3% and
90.9% for expectant management type II and III, respectively, and 90% and 77.8% for LAPV type II and III,
respectively.
CONCLUSION: LAPV in type II and III sFGR twins with arAWDV in the smaller fetus seems to yield outcomes
similar to those of less severe cases that received expectant management.
KEYWORDS: Twin Pregnancy; Monochorionic Pregnancy; Selective Fetal Growth Restriction; Expectant
Management; Laser Ablation of Placental Vessels; Perinatal Outcomes.
’ INTRODUCTION
Selective fetal growth restriction (sFGR) complicates 12-25%
of monochorionic-diamniotic (MCDA) twin pregnancies (1).
sFGR is defined as an estimated fetal weight (EFW) below
the 10th percentile for at least one twin and an EFW dis-
crepancy between the twinsX25% (2). Although the etiology
of this condition is not completely understood, unequal
placental sharing combined with different types of placental
anastomosis between the twins appears to play a key role in
the clinical manifestations and outcomes (1,3-5).
A classification system based on umbilical artery (UA)
Doppler flow of the smaller twin was proposed by Gratacós
et al. (1): in type I, there is positive end-diastolic flow in the
UA (pEDFUA); in type II, there is persistent absent/reversed
(ar) EDFUA; and in type III, there is intermittent absent/
reversed (iar) EDFUA (3). Type I cases have a good prognosis
and can be managed expectantly (6,7). Type II and III cases
carry a high risk of fetal/perinatal mortality and postnatal
handicap for both twins when managed expectantly. In these
cases, laser ablation of placental vessels (LAPV) and cord
occlusion of the smaller twin have been proposed as man-
agement options (1,8-11). Cord occlusion is an option when
selective reduction of the smaller twin is approved by the
parents and allowed by local regulations. Otherwise, LAPV
is available when cord occlusion is not possible for any reason,
but there is a paucity of information about whether compared
to expectant management, it improves perinatal outcomes.
In Brazil, selective termination of twins by cord occlusion
in cases of sFGR is not legal. Therefore, LAPV is the only
alternative to expectant management and has been offered in
some centers in the last six years. The aim of the present
study was to present the perinatal outcomes of type II and III
sFGR cases that received expectant management or LAPV.DOI: 10.6061/clinics/2018/e210
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’ MATERIALS AND METHODS
This was a retrospective study of all cases of sFGR managed
expectantly or treated by LAPV at the São Paulo University
(USP) Medical School and at the Heart Hospital, São Paulo,
Brazil, from 2007 to 2016. The study was approved by the
Institutional Review Board of USP (1.754.515).
The inclusion criteria were as follows: MCDA twin preg-
nancy with type II or III sFGR diagnosed before 26 weeks of
gestation, diagnosis and antenatal management at one of the
participating centers, no fetal or neonatal malformations, and
a cervical length of at least 15 mm (the 5th percentile accord-
ing to To et al. (12)) before the LAPV procedure. Patients
with twin oligo-polyhydramnios sequences (TOPS) or twin
anemia-polycythemia sequences (TAPS) were not included.
Chorionicity and amnionicity were determined on the first
trimester scan or on placental histological examination after
birth. sFGR was defined as an EFW below the 10th percentile
of local growth charts (13) for at least one twin and an EFW
discordance X25% (2). EFW discordance was calculated as
the difference between the EFW of the larger and the smaller
fetus divided by the EFW of the larger fetus, and the results
are expressed as a percentage. The type of sFGR was defined
according to the classification by Gratacós et al. (1).
Ultrasound and Doppler examinations were performed
transabdominally with a 3.5-5.0 MHz curvilinear-array trans-
ducer (Envisor-Phillips; Voluson Expert E8, General Electric
Healthcare; UGEO WS80a, Samsung; Accuvix XG, Samsung)
by operators with considerable experience in examining
twins. Doppler waveforms of the UA were assessed with a
minimum of three measurements on a free loop, avoiding
maternal and fetal breathing and movement.
All patients in the expectant management group received
antenatal care at the Multiple Pregnancy Unit of the Obstetrics
Department at USP Medical School, where MCDA pregnan-
cies are examined fortnightly up to 26 weeks of gestation
to detect TOPS, TAPS and sFGR. Pregnancies with a type II
or III UA pattern were followed twice a week until 26 weeks
of gestation. Since 2012, LAPV has been offered to patients
with an absent/reversed ‘‘a’’ wave in the ductus venosus
(arAWDV). At a gestational age (GA) X26 weeks, hospital
admission was considered for daily fetal monitoring in cases
of type II sFGR. For type III cases, ultrasound monitoring
was performed twice a week in the outpatient clinic. Deliv-
ery was indicated in the presence of arAWDV, abnormal
biophysical profile, fetal heart rate traces or persistent reverse
end diastolic flow by UA Doppler. Corticosteroid therapy
was administered when fetal deterioration was apparent.
The intervention (LAPV) group comprised patients who
underwent ultrasound evaluations and were treated by a
single operator (CFAP) at the Fetal Medicine and Surgery
Center (Gestar) and at the Heart Hospital. Since 2008,
endoscopic LAPV has been offered for the treatment of type
II and III sFGR with arAWDV before 26 complete weeks of
gestation. All patients who underwent the laser procedure
signed an informed consent. After the administration of loco
regional anesthesia, the LAPV procedure was performed
using a diode laser source (Medilas D’Skinpulse, Dornier
MedTech, Germany) at 30 to 40 W with a 1.2-mm semi-rigid
fiber optic endoscope (11530 AA, Karl Storz, Germany),
straight sheaths for posterior placentas (11530 KA or 11530
KC, Karl Storz), curved sheaths for anterior placentas (11530
KB or 11530 KC, Karl Storz), a trocar (11650 TG, Karl Storz)
and a 10 French cannula (Performa, Cook, Belgium) for use
with the 11530 KC sheaths. The procedure was conducted as
follows: the placental chorionic plate vessels through the
amniotic cavity of the larger fetus were initially mapped
endoscopically; the vascular equator (the expected location
of most arterio-venous anastomoses) was identified; and an
ablation line on the chorionic plate was created from one
edge of the placenta to the other, including arterio-venous
anastomoses and vessels with unknown courses (such as
those crossing the inter-twin membrane from the larger twin
to the growth-restricted twin). Caution was taken to preserve
vessels originating from and returning to the same fetus that
were surrounded by this ablation line. The cauterization
process was performed sufficiently slowly to create a visible
white line on the surface of the placenta. There was no
predefined minimum distance from the coagulation line to
the vessels that needed to be preserved. After the interven-
tion, patients remained in the hospital at least for 12 hours to
rest and received oral Nifedipine (20 mg, 8/8 hours) and
analgesics according to individual need.
Patients who underwent LAPV had their followups and
deliveries at the referring centers. Most cases in the expectant
management group delivered at USP Medical School.
Demographic characteristics of the mothers, ultrasound
and perinatal data, and information about the neonates up to
hospital discharge were obtained from medical records.
Perinatal outcomes of the expectant management and
LAPVare presented for type II and type III sFGR groups. The
main outcomes considered are gestational age at delivery
and survival rate. Perinatal outcomes are also presented
according to the larger and smaller twins.
Means and standard deviation (SD) or medians and range
were used to describe continuous variables, and absolute
and relative frequencies were calculated to describe the
categorical data.
Comparisons between expectant management and LAPV
treatment were not performed due to the unequal frequency
of arAWDV between the groups, which is the main indicator
of LAPV.
’ RESULTS
A total of 67 MCDA twin pregnancies with sFGR type II
(n=36) or type III (n=31) were included. In total, 83% (30/36)
of the type II cases and 29% (9/31) of the type III cases
underwent LAPV. Table 1 presents the baseline character-
istics of the study population according to the type of sFGR
and the management strategy. The smaller twin presented
with arAWDV in all the cases that underwent LAPV, whereas
none of the fetuses in the expectant management group
presented this finding at diagnosis.
Perinatal outcomes according to management strategy are
presented in Table 2. The overall fetal death rate was 25.4%
(34/134), with a rate of 30.6% (22/72) for type II sFGR cases
and 19.4% (12/62) for type III sFGR cases.
Premature rupture of membraneso32 weeks ando34 weeks
occurred in 17.14% (6/35) and 28.57% (10/35), respectively,
of the cases treated by LAPV. Overall, the main reasons for
delivery in the LAPV and expectant management groups
were preterm premature rupture of membranes, 40% (14/
35) versus 0% (0/27); abnormal fetal wellbeing, 34.3% (12/35)
versus 70.4% (19/27); threatened preterm labor, 8.6% (3/
35) versus 7.4% (2/27); death of one fetus, 5.7% (2/35) versus
14.8% (4/27); placental abruption, 2.9% (1/35) versus 0% (0/27);
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and spontaneous laborX34 weeks, 8.6% (3/35) versus 7.4%
(2/27).
’ DISCUSSION
In the present study, we described the perinatal outcomes
of LAPV and expectant management for MCDA twin preg-
nancies with type II and III sFGR. The findings demonstrate
that both management strategies seem to yield similar peri-
natal outcomes, provided that LAPV is adequately indicated
and performed by an experienced operator and that expectant
management cases are closely monitored. Our results sup-
port previous findings on expectant and laser management
strategies for type III sFGR (9). Recently, Peeva et al. (10)
have presented the outcomes of 142 type II sFGR pregnancies
subjected to laser photocoagulation of placental commu-
nicating vessels, and their data corroborate our findings
regarding laser treatment in cases of type II sFGR.
Three management options are available for type II and III
sFGR: expectant management, regardless of the severity of
the hemodynamic compromise in the smaller twin; LAPV, or
cord occlusion of the smaller twin, regardless of the DV flow
Table 1 - Baseline characteristics of the study population of monochorionic twin pregnancies with type II or III Doppler patterns
according to management strategy (expectant management or laser ablation of placental vessels).
Characteristics Expectant Laser
Type II, n=6 Type III, n=22 Type II, n=30 Type III, n=9
Maternal
Age, years 24.95 (17-34.2) 30.6 (17-45.7) 30 (15-39) 29 (18-38)
White ethnicity 3/6 (50) 17/22 (77.3) 19/30 (66.3) 8/9 (88.9)
Nulliparous 4/6 (66.7) 13/22 (59.1) 15/30 (50) 2/9 (22.2)
Pregnancy/ultrasound
GA at diagnosis/therapy, weeks 20 (16.43-22.57) 20.42 (16.57-26) 21.64 (17.86-25) 22.29 (17.57-26)
Severe cases* 5/6 (83.3) 18/22 (81.8) 30/30 (100) 9/9 (100)
Abnormal ductus venosus 0/6 0/22 (0) 30/30 (100) 9/9 (100)
EFW discordance at diagnosis/Laser 38.67 (4.52-57.27) 29.36 (1.69-46.7) 35.39 (25.35-61.73) 36.42 (27.27-40.65)
Data are presented as median (minimum-maximum) or number (%). GA, gestational age; EFW, estimated fetal weight. *Severe cases were defined by the
presence of any of the following criteria: early onset (i.e., GA o22 weeks), inter-twin estimated weight discordance 435%, and reverse end-diastolic
umbilical artery flow or abnormal ductus venosus (absent/reverse a-wave).
Table 2 - Perinatal outcomes of monochorionic twin pregnancies with type II or III Doppler patterns according to management
strategy (expectant management or laser ablation of placental vessels).
Outcome Expectant Laser
Type II, n=6 Type III, n=22 Type II, n=30 Type III, n=9
Latency to delivery, days 80.99 (47.04-113.96) 71.50 (36.05-119) 73.99 (45.01-137.97) 66.99 (28-108.99)
GA at delivery (weeks) 32.43 (26.71-37) 32.85 (27.71-37.71) 32.86 (27-38) 30.14 (26.86-36)
o28 weeks 1/5 (20) 1/20 (5) 1/29 (3.4) 2/7 (28.6)
o32 weeks 2/5 (40) 7/20 (35) 11/29 (37.9) 4/7 (57.1)
o34 weeks 3/5 (60) 17/20 (85) 16/29 (55.2) 5/7 (71.4)
Birth weight
Overall 975 (520-2770) 1555 (650-2300) 1504 (620-3300) 1317.5 (400-3400)
Smaller twin 620 (520-760) n=3 1215 (650-1880) n=18 1105 (620-2320) n=14 770 (400-1560) n=5
Larger twin 1430 (820-2770) n=5 1723 (1200-2300) n=20 1850 (600-3300) n=28 1455 (800-3400) n=7
Fetal death
Overall 4/12 (33.3) 6/44 (13.6) 18/60 (30) 6/18 (33.3)
Smaller twin 3/6 (50) 4/22 (18.2) 16/30 (53.3) 4/9 (44.4)
Larger twin 1/6 (16.7) 2/22 (9.1) 2/30 (6.7) 2/9 (22.2)
At least one live born 5/6 (83.3) 20/22 (90.9) 29/30 (96.7) 7/9 (77.8)
Two live born 3/6 (50) 18/22 (81.8) 13/30 (43.3) 5/9 (55.6)
GA at death (weeks) 23.5 (21.57-25.57) 31.71 (24.28-34.28) 24.13 (18.43-30) 25.28 (18.14-26.43)
Latency from diagnosis/LAPV to death (days) 19 (17-46) 64 (26-103) 10 (1-65) 3 (1-4)
Neonatal death
Overall 3/8 (37.5) 1/38 (2.6) 7/42 (16.7) 0/12 (0)
Smaller twin 2/3 (66.7) 1/18 (5.6) 5/14 (37.7) 0/5 (0)
Larger twin 1/5 (20) 0/20 (0) 2/28 (7.1) 0/7 (0)
Perinatal death
Overall 7/12 (58.3) 7/44 (14.9) 25/60 (41.7) 6/18 (33.3)
Smaller twin 5/6 (83.3) 5/22 (22.7) 21/30 (70) 4/9 (44.4)
Larger twin 2/6 (33.3) 2/22 (9.1) 4/30 (13.3) 2/9 (22.2)
At least one alive 5/6 (83.3) 20/22 (90.9) 27/30 (90) 7/9 (77.8)
Two alive 0/6 (0) 17/22 (77.3) 8/30 (26.7) 5/9 (55.6)
Intraventricular hemorrhage X grade 3
Overall 1/6 (16.7) 1/32 (3.1) 1/41 (2.4) 1/12 (8.3)
Smaller twin 0/1 (0) 1/15 (6.7) 1/14 (7.1) 1/5 (20)
Larger twin 1/5 (20) 0/17 (0) 0/27 (0) 0/7 (0)
Data are presented as median (minimum-maximum) or number (%).
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pattern at diagnosis; and LAPV, or cord occlusion of the
smaller twin, only in cases of arAWDV. As mentioned above,
cord occlusion for selective feticide in cases of sFGR is not an
option in several countries. Moreover, there are not sufficient
data to support any of the abovementioned management
options, and no randomized trials are currently ongoing to
elucidate this issue. Therefore, our study may be useful, as it
provides additional information on perinatal outcomes in
cases of sFGR managed according to the first or third options
described above.
We acknowledge that the groups in the present study are
not comparable, as all the cases in the LAPV group had
arAWDV at diagnosis, while none of the cases in the
expectant management group had this finding. However,
by demonstrating similarity in outcomes between the two
groups, one could conclude that LAPV in the presence of
severely abnormal DV flow prior to 26 weeks gestation at
least yielded results similar to those obtained with expectant
management of less severe cases. As arAWDV is an ominous
finding, it is very unlikely that a randomized trial comparing
LAPV to expectant management in these cases diagnosed
before viability will be conducted. Considering the high risk
of death of the smaller twin, it is highly unlikely that parents
will choose expectant management.
One potential limitation is the number of cases of each
management strategy based on sFGR type, with fewer expec-
tant management cases in the type II sFGR group and fewer
LAPV cases in the type III sFGR group. It is possible that
selection bias occurred, considering that all expectant man-
agement cases came from the National Health System (NHS),
and first trimester scans are not routinely performed for
these patients. The few type II sFGR cases that were referred
to USP Medical School Hospital consisted of patients who
had the chance to undergo an early scan and probably
presented with a less severe fetal compromise. The patients
who underwent LAPV predominantly had insurance or were
receiving private care and thus were followed beginning in
the first trimester with an adequate ultrasound schedule for
twins. Additionally, as demonstrated by others, type II sFGR
is the most severe, with a shorter latency from diagnosis
to fetal death or delivery compared to type III sFGR (1). It is
possible that several patients under NHS care suffered a
miscarriage before referral to USP Medical School Hospital.
The number of type III sFGR cases that underwent LAPV
was limited because this procedure was only indicated upon
identification of arAWDV, and the latency to fetal deteriora-
tion is longer compared to that for cases of type II sFGR (1,3).
This limitation also explains why only two patients under-
went LAPV at the USP Medical School Hospital during
the study period. These two cases were not included in the
present analysis because LAPV was performed by a different
operator. It was not the purpose of the present study to
compare the perinatal outcomes of type II and type III UA
Doppler patterns. Nevertheless, the perinatal outcomes for
both Doppler patterns were similar to those of previous
studies, with a worse prognosis for type II cases (1,6,14-16).
Specific comparisons between studies (1,6,8,14,17) are diffi-
cult due to heterogeneity in data presentation, laser indication
and type of intervention performed (laser or cord occlusion).
Moreover, due to the scarcity of these cases and the difficulties
in performing randomized studies, a meta-analysis of individual
patient data is a reasonable option to obtain sound evidence.
The main finding of this study is that in cases of type II
and III sFGR with arAWDVof the smaller twin, LAPV seems
to yield outcomes similar to those of expectant management
for less severe sFGR cases (without arAWDV of the smaller
twin). This finding may help in cases with arAWDV, in those
situations where patients are reticent about invasive proce-
dures, to decide toward the LAPV.
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